期刊文献+

早期识别和评估脓毒性休克的研究进展 被引量:2

Advances in the early Identification and Assessment of Septic Shock
下载PDF
导出
摘要 脓毒性休克是脓毒症合并出现的严重循环障碍和细胞代谢紊乱的感染性疾病,有较高病死率,是急危重症医学面临的重要临床问题。目前脓毒性休克的发病率依旧处于升高态势,并且已成为世界范围内病危与死亡的主因,即便患者存活,也会存在长期的认知、心理和生理障碍。早期识别、评估与恰当处理是降低脓毒性休克死亡率的关键。现通过对脓毒性休克的定义、诊断标准、早期临床表现和生物标志物进行综述,为今后此类患者的早期诊断及治疗提供参考,以提高患者生存率,改善患者临床预后。 Septic shock is an infectious disease with severe circulatory disturbance and cell metabolic disorder in sepsis.it has a high mortality rate and is an important clinical problem in critical care medicine.The incidence of septic shock is still on the rise,and has become the leading cause of death and death worldwide.Even if patients survive,there will be long-term cognitive,psychological and physiological disorders.Early identification,evaluation and proper management are the keys to reduce the mortality of septic shock.This article reviews the definition,diagnostic criteria,early clinical manifestations and biomarkers of septic shock in order to provide references for the early diagnosis and treatment of septic shock in order to improve the survival rate and clinical prognosis.
作者 范丽丽 FAN Lili(Emergency Department,Linyi Hospital of traditional Chinese medicine,Linyi Shandong 276000,China)
出处 《临床研究》 2021年第9期196-198,共3页 Clinical Research
关键词 脓毒性休克 早期诊断 脓毒症 综述 septic shock early diagnosis sepsis review
  • 相关文献

参考文献15

二级参考文献198

  • 1Whang KT, Vath SD, Becker KL, et al. Procalcitonin and pro-inflammatory cytokine interactions in sepsis [ J]. Shock,2000,14(1): 73-78.
  • 2Nijsten MW, Olinga P, The TH,et al. Procalcitonin behaves as a fastresponding acute phase protein in vivo and in vitro [ J]. Crit Care Med, 2000, 28 (2): 458461.
  • 3Wiedermann FJ,Kaneider N,Egger P, et al. Migration of human monocytes in response to procalcitonin [J]. Crit Care Med, 2002 , 30(5): 1112-1117.
  • 4Hoffmann G, Totzke G, Seibel M, et al. In vitro modulation of inducible nitric oxide synthase gene expression and nitric oxide synthesis by procalcitonin [J]. Crit Care Med, 2001, 29 (1): 112-126.
  • 5Morgenthaler NG, Struck J, Chancerelle Y,et al. Production of procalcitonin (PCT) in non-thyroidal tissue after LPS injection [J]. Horm Metab Res, 2003 , 35 ( 5): 290-295.
  • 6Meisner M, Tschaikowsky K, Schnabel S, et al. Procalcitonin- influence of temperature,storage,anticoagulation and arterial or venous asservation of blood samples on procalcitonin concentrations [J]. EurJ Clin Chem Clin Biochem, 1997 , 35 ( 8): 597-601.
  • 7Huang DT, Weissfeld LA, Kellum JA, et al. Risk prediction with procalcitonin and clinical rules in community-acquired pneumonia [J]. Ann Emerg Med, 2008 , 52 (1): 48-58.
  • 8Kruger S, Ewig S, Marre R, et al. Procalcitonin predicts patients at low risk of death from community-acquired pneumonia across all CRB-65 classes [J]. Eur Respir J,2008,31 (2): 349-355.
  • 9Hirakata Y,Yanagihara K, Kurihara S, et al. Comparison of usefulness of plasma procalcitonin and C-reactive protein measurements for estimation of severity in adults with community-acquired pneumonia [J]. Diagn Microbiol Infect Dis, 2008 , 61 (2): 170-174.
  • 10Chan YL, Tseng CP, Tsay PK, et al. Procalcitonin as a marker of bacterial infection in the emergency department : an observational study[J]. Crit Care, 2(XM, 8 (1): R12-20.

共引文献755

同被引文献33

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部